Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Arcus Biosciences, Inc.NYSE: RCUS
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit declines year over year
Q2 FY2026 gross profit of $41M fell 74.4% year over year, behind the -58.0% change in trailing-twelve-month gross profit. Sequentially, it rose 173.3% from the prior quarter. Over 3 fiscal years it compounded at +28.4% a year.
Context
- Gross profit amounted to 96.0% of revenue in FY2025, down 4.0 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -74.4% toward the trailing-twelve-month pace of -58.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 237M USD
- Year-over-year change
- -8.1%
- 4-year CAGR
- -11.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 237M | -8.1% |
| FY2024 | 2024-12-31 | 258M | +120.5% |
| FY2023 | 2023-12-31 | 117M | +4.5% |
| FY2022 | 2022-12-31 | 112M | -70.8% |
| FY2021 | 2021-12-31 | 383M | — |
Gross Profit vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 gross profit of $110M is the 4th highest of the 9 companies compared; the peer median is $62.51M.
- Its year-over-year change of -58.0% is the 7th highest of 8, against a peer median of +125.6%.
- Gross profit amounts to 94.0% of revenue for RCUS, versus a peer median of 92.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $416.98M | +2967.4% | +123.0% | 92.5% | |
| LTM Sep 2026 | $176.5M | +125.6% | +676.9% | 96.7% | |
| LTM Jun 2026 | $156.04M | +158.9% | — | 100.0% | |
| LTM Jun 2026 | $110M | -58.0% | +28.4% | 94.0% | |
| LTM Jun 2026 | $70.81M | +23115.4% | +241.9% | 99.6% | |
| LTM Mar 2026 | $54.21M | +83.5% | +50.2% | 82.1% | |
| LTM Mar 2026 | $45.4M | -16.1% | -1.2% | 87.2% | |
| LTM Jun 2026 | -$2.2M | — | — | 61.0% | |
| LTM Jun 2026 | -$2.33M | -101.6% | — | — | |
| Peer median (excluding RCUS) | $62.51M | +125.6% | +123.0% | 92.5% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.